Pharmacokinetics and Safety of BI 695502 in Healthy Subjects: a Randomized, Single-blind, Single-dose, Parallel-arm, Active-comparator Clinical Phase I Study

Trial Profile

Pharmacokinetics and Safety of BI 695502 in Healthy Subjects: a Randomized, Single-blind, Single-dose, Parallel-arm, Active-comparator Clinical Phase I Study

Discontinued
Phase of Trial: Phase I

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Haematological malignancies; Solid tumours
  • Focus Pharmacokinetics
  • Acronyms INVICTAN-1
  • Sponsors Boehringer Ingelheim; Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 01 Aug 2017 Primary endpoint of AUC of the analyte in plasma from time zero extrapolated to infinity has been met, according to results published in the Expert Opinion on Investigational Drugs.
    • 01 Aug 2017 Results published in the Expert Opinion on Investigational Drugs
    • 01 Aug 2017 Status changed from recruiting to discontinued according to results published in the Expert Opinion on Investigational Drugs.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top